House Committee Calls On EPO Marketers To Provide Information, Halt DTC Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
Inquiry also requests Amgen and Johnson & Johnson cease financial incentives to physicians.
You may also be interested in...
EPO Aggressive Dosing May Be Curtailed By New Black Box Warning
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.
Boxed Warning In Development For Procrit, Aranesp
Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: